Shigeyuki Toyoizumi

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Rheumatoid Arthritis

Locally Advanced

Metastatic Breast Cancer

Top Venues

Rheumatology and therapy

Journal of gastroenterology and hepatology

Breast cancer (Tokyo, Japan)

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Masayoshi Harigai, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Naohiro Sugitani, Shigeyuki Toyoizumi, Naonobu Sugiyama, Hisashi Yamanaka
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry. Rheumatology and therapy (2024)
Haruru Kotani, Norikazu Masuda, Toshinari Yamashita, Yoichi Naito, Tetsuhiko Taira, Kenichi Inoue, Masato Takahashi, Kan Yonemori, Shigeyuki Toyoizumi, Yuko Mori, Takashi Nagasawa, Natsuki Hori, Hiroji Iwata
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study. Breast cancer (Tokyo, Japan) 29 (6) (2022)
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon-Suk Woo, Toshifumi Hibi
Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. Journal of gastroenterology and hepatology 37 (10) (2022)
Yoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda, Kenichi Harano, Nobuaki Matsubara, Shigeyuki Toyoizumi, Yuko Mori, Natsuki Hori, Takashi Nagasawa, Takahiro Kogawa
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. Investigational new drugs 39 (6) (2021)